Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $67.70

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned a consensus rating of “Buy” from the twelve brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $67.70.

A number of equities analysts have recently issued reports on the stock. Scotiabank cut their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Thursday, November 14th. Stifel Nicolaus started coverage on Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, Leerink Partners began coverage on shares of Janux Therapeutics in a research note on Friday, November 22nd. They set an “outperform” rating and a $79.00 price target for the company.

Insiders Place Their Bets

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the transaction, the insider now owns 3,162,851 shares of the company’s stock, valued at $132,839,742. This trade represents a 3.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $51.60, for a total value of $1,290,000.00. Following the completion of the transaction, the chief executive officer now directly owns 257,054 shares of the company’s stock, valued at approximately $13,263,986.40. This represents a 8.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 445,610 shares of company stock valued at $20,578,666 in the last three months. 29.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently made changes to their positions in the business. FMR LLC raised its holdings in shares of Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares during the period. Janus Henderson Group PLC increased its position in Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after buying an additional 721,563 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares during the period. Logos Global Management LP lifted its position in shares of Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after buying an additional 600,000 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after acquiring an additional 38,490 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

Shares of JANX opened at $46.39 on Tuesday. The firm has a market cap of $2.43 billion, a PE ratio of -39.65 and a beta of 3.52. Janux Therapeutics has a 52-week low of $7.79 and a 52-week high of $65.60. The business’s 50 day moving average price is $49.98 and its two-hundred day moving average price is $45.83.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company’s revenue was down 82.6% on a year-over-year basis. Research analysts predict that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.